COLL — COLLEGIUM PHARMACEUTICAL, INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1267565 ·
Last close
$22.53
Market Cap
$698.41M
52W High
$50.79
52W Low
$21.65
ADV30
874,247
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 199,878,000 | 110,292,000 | 3,698,000 | -15,051,000 | 2,135,790,000 | 129,467,000 | 1,823,881,000 |
| Mar 2026 | 193,520,000 | 117,246,000 | 30,896,000 | 14,496,000 | 1,651,955,000 | 268,648,000 | 1,339,533,000 |
| Dec 2025 | 205,449,000 | 128,378,000 | 60,738,000 | 16,963,000 | 1,656,834,000 | 231,252,000 | 1,355,159,000 |
| Sep 2025 | 209,361,000 | 129,171,000 | 62,068,000 | 31,507,000 | 1,607,328,000 | 150,096,000 | 1,332,520,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$329,922,000
Investing CF
$-551,901,000
Financing CF
$234,108,000
CapEx
$-1,643,000
Dividends Paid
—
Buybacks
$-25,025,000
EPS Diluted TTM
$1.24
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-101,684,000
Inventory
$113,269,000
Receivables
$285,102,000
ST Investments
$0
EBIT TTM
$154,120,000
Pretax Income TTM
$77,680,000
Interest Exp TTM
$76,440,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$808,208,000
EBITDA
$405,255,008
Free Cash Flow
$324,038,496
Enterprise Value
$1,829,055,232
Total Cash
$129,467,000
Total Debt
$1,217,881,984
Shares Out
30,999,193
Trailing EPS
$1.27
Book Value
$9.60
ROE
17.6%
ROA
5.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 780,567,000 | 178,454,000 | 62,870,000 | 1,656,834,000 | 1,355,159,000 | 301,675,000 | 329,323,000 |
| Dec 2024 | 631,449,000 | 166,981,000 | 69,190,000 | 1,663,591,000 | 1,434,749,000 | 228,842,000 | 204,980,000 |
| Dec 2023 | 566,767,000 | 166,961,000 | 48,155,000 | 1,143,308,000 | 947,877,000 | 195,431,000 | 274,749,000 |
| Dec 2022 | 463,933,000 | 33,319,000 | -25,002,000 | 1,174,131,000 | 979,289,000 | 194,842,000 | 124,230,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$6.62
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $22.50 · spot: $22.91 · call volume: 242 · put volume: 0Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VSTM | Verastem, Inc. | $700.96M | $7.74 | — |
| SLN | Silence Therapeutics plc | $694.88M | $11.18 | — |
| ANNX | Annexon, Inc. | $690.07M | $3.64 | — |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $682.44M | $4.13 | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $727.09M | $34.45 | — |
News headlines (Yahoo Finance, 1h cache)
3 Value Stocks That Fall Short
2026-09-28 09:58 · Yahoo
5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call
2026-08-15 11:25 · Yahoo
Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript
2026-08-13 12:29 · Yahoo
Collegium Announces $50 Million Accelerated Share Repurchase Program
2026-08-13 11:30 · Yahoo
COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance
2026-08-10 01:49 · Yahoo
Collegium Pharmaceutical Q2 Earnings Call Highlights
2026-08-06 13:04 · Yahoo
Collegium Pharmaceutical (NASDAQ:COLL) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops
2026-08-06 12:28 · Yahoo
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
2026-08-06 11:30 · Yahoo
Collegium Pharmaceutical, Inc. Q2 2026 Earnings Call Summary
2026-08-07 03:27 · Yahoo
1 Oversold Stock Ready to Bounce Back and 2 We Find Risky
2026-09-22 10:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.